

[1]熊艳丽,杨雪琴,张诗珩,等.Nm23-H1在小细胞肺癌中的表达及其与预后的关系[J].第三军医大学学报,2014,36(10):983-986.

Xiong Yanli, Yang Xueqin, Zhang Shiheng, et al. Expression of Nm23-H1 and its relationship with prognosis in patients with small cell lung cancer[J]. J Third Mil Med Univ, 2014, 36(10): 983-986.

[点击复制](#)

Nm23-H1在小细胞肺癌中的表达及其与预后的关系

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R] 卷: 36 期数: 2014年第10期 页码: 983-986 栏目: 论著 出版日期: 2014-05-30

Title: Expression of Nm23-H1 and its relationship with prognosis in patients with small cell lung cancer

作者: [熊艳丽](#); [杨雪琴](#); [张诗珩](#); [杨宇馨](#); [冯燕](#); [黄环](#); [王东](#)
第三军医大学大坪医院野战外科研究所肿瘤中心

Author(s): [Xiong Yanli](#); [Yang Xueqin](#); [Zhang Shiheng](#); [Yang Yuxin](#); [Feng Yan](#); [Huang Huan](#); [Wang Dong](#)
Cancer Center, Institution of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing, 400042, China

关键词: [小细胞肺癌](#); [转移](#); [Nm23-H1](#); [预后](#)

Keywords: [small cell lung cancer](#); [metastasis](#); [Nm23-H1](#); [prognosis](#)

分类号: R341; R730.23; R734.2

文献标志码: A

摘要: 目的 探讨肿瘤转移抑制因子Nm23-H1在小细胞肺癌 (small cell lung cancer, SCLC) 中的表达及其与预后的关系。 方法 通过免疫组化S-P法检测71例SCLC组织和22例正常肺组织中Nm23-H1蛋白表达情况, 根据染色强度和阳性肿瘤细胞数目所占百分比, 将其分为高、低表达两组, 使用SPSS 19.0软件统计分析Nm23-H1的表达与临床病理及预后的关系。 结果 正常肺组织中Nm23-H1蛋白表达显著高于SCLC组织 (90.9% vs 57.7%, $P < 0.01$); 局限期患者Nm23-H1蛋白表达显著高于广泛期患者 (66.7% vs 39.1%, $P < 0.05$)。多因素Logistic回归分析显示, Nm23-H1蛋白可作为SCLC是否转移的独立保护因素 ($OR = 0.32$, $95\%CI = 0.12 - 0.90$, $P < 0.05$)。亚细胞定位在正常肺组织与肺癌组织中没有差异, 在不同分期之间也没有差异。多因素COX风险回归分析表明只有临床分期为广泛期和年龄 ≥ 60 岁是SCLC患者总生存的劣势预后因素 (年龄: $HR = 1.03$, $95\%CI = 1.00 - 1.05$, $P < 0.05$; 临床分期: $HR = 1.85$, $95\%CI = 1.03 - 3.33$, $P < 0.05$)。Nm23-H1蛋白表达及亚细胞定位与SCLC患者生存期都没有显著相关性。 结论 Nm23-H1在SCLC组织中以细胞质表达为主的低表达, 低表达与SCLC的远处转移密切相关, 可能是SCLC预后不良的指标之一。

Abstract: Objective To study the expression of Nm23-H1 and its relationship with prognosis in patients with small cell lung cancer. Methods The expression of Nm23-H1 was detected by immunohistochemistry in 71 small cell lung cancer tissue samples and 22 normal lung tissue samples. According to their positive

导航/NAVIGATE

[本期目录/Table of Contents](#)

[下一篇/Next Article](#)

[上一篇/Previous Article](#)

工具/TOOLS

[引用本文的文章/References](#)

[下载 PDF/Download PDF\(1049KB\)](#)

[立即打印本文/Print Now](#)

[查看/发表评论/Comments](#)

[导出](#)

统计/STATISTICS

[摘要浏览/Viewed](#) 66

[全文下载/Downloads](#) 47

[评论/Comments](#)

[RSS](#) [XML](#)

percentage and staining intensity, they were divided into 2 groups: high expression group and low expression group. The correlation of Nm23-H1 expression with clinicopathology and prognosis was performed by SPSS 19.0.

Results The positive rate of Nm23-H1 was higher in normal tissue samples than in small cell lung cancer (90.9% vs 57.7%, $P < 0.05$); It was higher in limited stage than in extensive stage small cell lung cancer (66.7% vs 39.1%, $P < 0.05$). Multivariate logistic regression showed the Nm23-H1 expression was an independent protect factor for the metastasis of small cell lung cancer ($OR = 0.32, 95\% CI = 0.12 - 0.90, P < 0.05$). The subcellular location of the Nm23-H1 showed no difference between normal lung tissues and cancer tissues, neither between different stages. In the survival analysis, Nm23-H1 positive expression was found to be related with decreased median overall survival than negative expression patients ($P < 0.05$). The stage was also associated with mOS that the patients with limited foci stayed longer than those with metastatic disease ($HR = 1.85, 95\% CI = 1.03 - 3.63, P < 0.05$).

Conclusion Nm23-H1 is midly expressed in SCLC cancer tissues, and mainly in the cytoplasm. The expression plays an important role in the metastasis of SCLC, and may be a predictive factor for the poor outcome of SCLC.

参考文献/REFERENCES:

熊艳丽, 杨雪琴, 张诗珩. Nm23-H1在小细胞肺癌中的表达及其与预后的关系[J]. 第三军医大学学报, 2014, 36(10): 983-986.

相似文献/REFERENCES:

- [1] 吴晓慧, 王顺祥, 王士杰, 等. 肝癌组织中Raf激酶抑制蛋白的表达及其临床意义[J]. 第三军医大学学报, 2009, 31(05): 416.
WU Xiao-hui, WANG Shun-xiang, WANG Shi-jie, et al. Expression and significance of Raf kinase inhibitor protein in hepatocellular carcinoma: report of 72 cases[J]. J Third Mil Med Univ, 2009, 31(10): 416.
- [2] 卢先锋, 戴楠, 杨宇馨, 等. 血清uPAR的水平与小细胞肺癌化疗疗效及预后的关系[J]. 第三军医大学学报, 2012, 34(22): 2318.
Lu Xianfeng, Dai Nan, Yang Yuxin, et al. Serum uPAR and its relationship with chemosensitivity and prognosis in patients with small cell lung cancer[J]. J Third Mil Med Univ, 2012, 34(10): 2318.
- [3] 杨腾炎, 曹国强. 支气管类癌误诊为小细胞肺癌1例[J]. 第三军医大学学报, 2012, 34(23): 2348.
- [4] 李佩佩, 梁丽峰, 常蕊静, 等. 3株人小细胞肺癌细胞系细胞线粒体DNA基因组突变研究[J]. 第三军医大学学报, 2013, 35(03): 216.
Li Peipei, Liang Lifeng, Chang Ruijing, et al. Mitochondrial DNA mutations in human small cell lung cancer cell lines[J]. J Third Mil Med Univ, 2013, 35(10): 216.
- [5] 余祖滨, 白莉, 姚珂, 等. SOCS3对肺腺癌细胞株A549迁移和侵袭能力的影响[J]. 第三军医大学学报, 2008, 30(07): 588.
YU Zu-bin, BAI Li, YAO Ke, et al. Effects of SOCS3 gene on migration and invasion of lung adenocarcinoma cell line A549[J]. J Third Mil Med Univ, 2008, 30(10): 588.
- [6] 孙梯业, 赵永亮, 颜伟, 等. CXCR4在VEGF-C介导的胃癌淋巴道转移中的作用[J]. 第三军医大学学报, 2008, 30(02): 161.
SUN Ti-ye, ZHAO Yong-liang, YAN Wei, et al. Role of CXCR4 in lymph node metastasis promoted by VEGF-C in gastric carcinoma[J]. J Third Mil Med Univ, 2008, 30(10): 161.
- [7] 郭芮伶, 吴国明, 戢福云, 等. DNA错配修复基因甲基化在H446细胞获得性耐药中的作用[J]. 第三军医大学学报, 2007, 29(23): 2247.
GUO Rui-ling, WU Guo-ming, JI Fu-yun, et al. Methylation of DNA mismatch repair gene MLH1 and MSH2 in acquired multidrug-resistance of human small cell lung cells H446[J]. J Third Mil Med Univ, 2007, 29(10): 2247.
- [8] 易龙, 张乾勇, 糜漫天, 等. ω -3多不饱和脂肪酸抑制人前列腺癌细胞黏附和侵袭的体外实验研究[J]. 第三军医大学学报, 2007, 29(05): 396.
YI Long, ZHANG Qian-yong, MI Man-tian, et al. Effects of ω -3 polyunsaturated fatty acid on adhesion and invasion of human prostate cancer PC-3 cells in vitro[J]. J Third Mil Med Univ, 2007, 29(10): 396.
- [9] 李昆霖, 吴国明, 戢福云, 等. 人小细胞肺癌多药耐药细胞差异表达基因的克隆研究[J]. 第三军医大学学报, 2006, 28(24): 2403.
- [10] 张晓晶, 王甦, 刘云鹏, 等. EGFR信号通路调控结肠癌Caco-2细胞侵袭转移的分子机制[J]. 第三军医大学学报, 2006, 28(14): 1479.
- [11] 李玮, 林萍, 王骥. 广泛期小细胞肺癌转移状态对生存的影响[J]. 第三军医大学学报, 2010, 32(17): 1861.
Li Wei, Lin Ping, Wang Qi. Effect of extensive small cell lung cancer metastasis on patient's survival[J]. J Third Mil Med Univ, 2010, 32(10): 1861.